Modelling chemotherapy-induced cardiotoxicity by human pluripotent stem cells

Rosalinda Madonna, Christian Cadeddu, Martino Deidda, Paolo Spallarossa, Concetta Zito, Giuseppe Mercuro

Research output: Contribution to journalReview articlepeer-review


Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC)-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.

Original languageEnglish
JournalCurrent Drug Targets
Issue number16
Publication statusPublished - Jan 1 2016


  • Cardiac stem cells
  • Chemotherapy-induced cardiotoxicity
  • Pluripotent stem cells
  • Preclinical models

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Modelling chemotherapy-induced cardiotoxicity by human pluripotent stem cells'. Together they form a unique fingerprint.

Cite this